Scientific Program


Wednesday, 17. October 2018
07:15Registration
08:00Welcome
08:15

Session 1: Immunogenicity/Biomarker
Chairs: 
Therasa L. Whiteside, Pittsburgh, USA | Jochen Hess, Heidelberg, Germany

Human leukocyte antigens and haplotypes allow for prognostic classification of HNSCC patients
Gunnar Wichmann, Leipzig, Germany

Breaking the brakes: Targeting immune suppressive cells
Marco C. Merlano, Cuneo, Italy

Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
Ezra Cohen, San Diego, USA

Immunotherapy and Head and Neck Cancer : Focus on recurrent and metastatic disease
Robert Haddad, Boston, USA

09:45Coffee break / Industrial Exhibtion / Poster
10:15

Session 2: Liquid Biopsy
Chairs: 
Marco C. Merlano, Cuneo, Italy | Robert Haddad, Boston, USA

Extracellular Vesicles as biomarkers for cancer progression and cancer associated VTE
Frank Gieseler, Lübeck, Germany

Immune modulation by extracellular vesicles released from mesenchymal cells
Martina Seifert, Berlin, Germany

Monitoring ctDNA in Liquid Biopsy for Cancer Therapy - Facts and Hopes
Jochen Hess, Heidelberg, Germany

The potential diagnostic/prognostic role of plasma-derived exosomes in HNSCC
Therasa L. Whiteside, Pittsburgh, USA

11:45

Posters of the day
Chair: 
Ezra Cohen, San Diego, USA

Regulatory T cells in endogenous mouse lymphoma are antigen-specific nTregs and provide a target for immune checkpoint-inhibiting therapies (P14)
Vera Bauer, Munich, Germany

The role of NFATc1 in T cell-mediated immune responses during the development of lung cancer (P05) 
Lisanne Heim, Erlangen, Germany

Activation of MDA5 improves anti-tumor therapy and reduces suppressive capacity of myeloid-derived suppressor cells (P11) 
Phillip Metzger, Munich, Germany

12:30

Industry Symposium with Snack
MSD Sharp & Dohme GmbH

SCCHN: Current state and future trends
Chair:
Viktor Grünwald, Germany

R/M SCCHN - Today
Tanguy Seiwert, USA

R/M SCCHN - Tomorrow
Viktor Grünwald, Germany

R/M SCCHN - Soon?
Andreas Dietz, Germany

13:30Postersession
All presenters are asked to be present at their poster.
14:15

Session 3: Cellular vaccines
Chairs:
Bernardo S. Franklin, Bonn, Germany | Hans-Georg Rammensee, Tübingen, Germany

CAR NK cells for cancer retargeting
Ulrike Koehl, Leipzig, Germany

Immune biological rationale for the design of radioimmunotherapies
Udo Gaipl, Erlangen, Germany

Role of resident memory T cells in cancer immunotherapy
Eric Tartour, Paris, France

Perspectives of gd T cells in cancer immunotherapy
Dieter Kabelitz, Kiel, Germany

15:45Coffee break / Industrial Exhibtion / Poster
16:15

Session 4: New targets I
Chairs:
Ulrike Koehl, Leipzig, Germany | Eric Tartour, Paris, France

On the development of personalized cancer vaccines
Hans-Georg Rammensee, Tübingen, Germany

Platelets regulate innate immunity in autoinflammtory diseases and cancer
Bernardo S. Franklin, Bonn, Germany

A Pan-cancer Landscape of Interactions between Tumors and infiltrating immune cells
David Tamborero, Stockholm, Sweden

In vivo Imaging of Immune Cell Interactions in Tumor Draining Lymph Nodes of SCCHN
Stephan Lang, Essen, Germany

18:00Scientific Get-together at the Posters
Apéro with Wine, Cheese and Jazz

Thursday, 18. October 2018
08:15

Session 5: Microbiome
Chair:
Viktor Umansky, Heidelberg, Germany

Title t.b.d.
Philip Rosenstiel, Kiel, Germany

The role of the gut microbiome in chronic diseases
Matthias Laudes, Kiel, Germany

Tumor and host factors regulating anti-tumor immunity and immotherpy efficacy
Thomas F. Gajewski, Chicago, USA

09:30Coffee break / Industrial Exhibtion / Poster
10:00

Session 6: Resistance/Immunosuppression
Chairs:
Barbara Wollenberg, Lübeck, Germany | Thomas F. Gajewski, Chicago, USA

PD1+X: early clinical trials with novel immunotherapy combinations
Ulrich Keilholz, Berlin, Germany

MDSC as a new target for cancer immunotherapy
Viktor Umansky, Heidelberg, Germany

Neo-adjuvant checkpoint inhibition – the pathway towards personalized immunotherapy
Christian Blank, Amsterdam, Netherlands

Interference between tumor mutational burden, HPV status, immune signatures and outcome in patients with head and neck cancer treated with chemoradiotherapy
Ingeborg Tinhofer-Keilholz, Berlin, Germany

11:30

Posters of the day
Chair:
Ralph Pries, Lübeck, Germany

Combining anti-VEGF-A and anti-PD-L1 therapy prolongs overall survival in small cell lung carcinomas (P26)
Lydia Meder, Cologne, Germany

Pre- and intratherapeutic cellular monitoring for dose adjustment of chemotherapy in aggressive lymphoma (P25)
Julia Schröder, Brandenburg, Germany

Killing melanoma cells with ROS provides immuno-protection against tumor growth in vivo (P24)
Sander Bekeschus, Greifswald, Germany

12:00

Industry Symposium with Snack
Bristol-Myers Squibb GmbH & Co KG aA

From a clinical perspective: New developments in immuno-oncology – therapy, biomarkers and pipeline

Angela Krackhardt, Munich, Germany
Barbara Wollenberg, Lübeck, Germany

13:00Postersession
All presenters are asked to be present at their poster.
13:30

Session 7: Combinational strategies 
Chairs:
Barbara Seliger, Halle, Germany | Thomas Blankenstein, Berlin, Germany

Dynamics of Conversation: Immunotherapy meets Tumor Microenvironment
Iris Helfrich, Essen, Germany

Development of personalized treatment and novel monitoring approaches for T-cell based immunotherapies in cancer
Angela Krackhardt, München, Germany

Modulating the tumor microenvironment
Dirk Jäger, Heidelberg, Germany

Priming anti-tumor immunity by radiotherapy
Kirsten Lauber, München, Germany

15:00Coffee break / Industrial Exhibtion
15:30

Session 8: New targets II
Chairs:
Angela Krackhardt, München, Germany | Iris Helfrich, Essen, Germany

Revision of immune escape mechanisms as novel therapeutic strategy
Barbara Seliger, Halle, Germany

T cell receptor gene therapy
Thomas Blankenstein, Berlin, Germany

Myeloid cells as biomarkers and therapeutic targets for cancer patients.
Licia Rivoltini, Mailand, Italy

17:00Wrap-up & Farewell

List of Posters


All presenters are asked to be present at their poster during the poster sessions.

(I) Immunomodulation / Tumor Biology
P01

Phenotype compartments and spatial distribution of clonally expanded T cells and their target antigens in rectal cancer
Livius Penter, Berlin, Germany

P02

Integrin β4 synergizes with E-and P-selectin to regulate tumor growth: Unravelling the molecular mechanisms
Sandra Hanika, Hamburg, Germany

P03

Immune suppression in sentinel lymph nodes draining HPV-negative head and neck cancer
Rieneke van de Ven, Amsterdam, Netherlands

P04

Primary and recurrent head and neck squamous carcinomas are strikingly different regarding their immune microenvironment
Christian Watermann, Lübeck, Germany

P05

The role of NFATc1 in T cell-mediated immune responses during the development of lung cancer
Lisanne Heim, Erlangen, Germany

P06

Role of glycolysis for intestinal inflammation and carcinogenesis
Felix Sommer, Kiel, Germany

P07

Epithelial RNase H2 Maintains Genome Integrity and Prevents Intestinal Tumorigenesis in Mice
Konrad Aden, Kiel

P08

MALDI-imaging: Identification of protein signatures of genomic instability in colorectal cancers
Timo Gemoll, Lübeck, Germany

P09

Investigating a potential role of Got1 in T cell exhaustion.
Nina Weißhaar, Heidelberg, Germany

(II) New Targets
P10

Biparatopic heavy chain antibodies (bi-hcAbs): fusion of two distinct CD38-specific nanobodies into a human IgG1 bi-hcAb results in potent CDC vs. myeloma cells
Julia Hambach and Katharina Petry, Hamburg, Germany

P11

Activation of MDA5 improves anti-tumor therapy and reduces suppressive capacity of myeloid-derived suppressor cells
Philipp Metzger, Munich, Germany

P12

Effect of both PD-1/PD-L1 and ERK inhibitor on Cisplatin-sensitive (HEY) and Cisplatin-resistant (HEY-Cis) ovarian cancer cell lines
Karen Bräutigam, Lübeck, Germany

P13

Effect of both PD-1/PD-L1 and ERK inhibitor on triple negative breast cancer cell lines and the non-triple negative cell line MCF-7
Karen Bräutigam, Lübeck, Germany

P14

Regulatory T cells in endogenous mouse lymphoma are antigen-specific nTregs and provide a target for immune checkpoint-inhibiting therapies
Vera Bauer, München, Germany

P15

Specific Targeting of Oncogenic Mutations Using CRISPR-Technology to Destroy Activated Oncogenes and Enhance Immune Response
Felix Oppel, Bochum, Germany

All presenters are asked to be present at their poster during the poster sessions.

(III) Therapy prognosis / prediction
P16

Effects of EGFR-MEK-ERK pathway on PD-L1 expression in head and neck squamous cell carcinoma
Jochen Hess, Heidelberg, Germany

P17

The emerging role of extracellular vesicles in clinical research inflammation, cancer progression, metastasis
Fanny Ender, Luebeck, Germany

P18

Identification, characterization and validation of neoantigens and neoantigen-reactive T cells in their distinct tumor microenvironment of patients included in the ImmuNEO MASTER pan-cancer cohort
Celina Schwencke-Westphal, Munich, Germany

P19

CD8+ T cell response to HPV16 E7 predicts survival outcome in oropharyngeal cancer
Holger Sudhoff, Bielefeld, Germany

(IV) Therapeutic strategies / approaches
P20

Current status of radiotherapy/radiochemotherapy and immunotherapy combinations– a German survey
Lukas Käsmann, Munich, Germany

P21

ACTIVATION OF IMMUNE RESPONSE IN REFRACTORY PATIENTS TO STANDARD TREATMENT
Andrea Abbona, Cuneo, Italy

P22

Which adjuvants for tumor-antigen vaccination induce powerful non-sialylated IgG antibodies?
Marc Ehlers, Luebeck, Germany

P23

Irradiation-induced cell death modalities and dying cell clearance: Relevance for tumor radiosensitivity, clonogenic survival, and the outcome of radiotherapy
Nikko Brix, Munich, Germany

P24

Killing melanoma cells with ROS provides immuno-protection against tumor growth in vivo
Sander Bekeschus, Greifswald, Germany

P25

Pre- and intratherapeutic cellular monitoring for dose adjustment of chemotherapy in aggressive lymphoma
Julia Schröder, Brandenburg, Germany

P26

Combining anti-VEGF-A and anti-PD-L1 therapy prolongs overall survival in small cell lung carcinomas
Lydia Meder, Cologne, Germany

P27

Robust GMP manufacturing process with IL-2 and a glycoprotein antibody cocktail generates highly active human NK cell batches for cancer immunotherapy
Katharina Bröker, Brandenburg a. d. Havel, Germany

P28

Progression of head and neck cancer is associated with elevated neutrophil extracellular traps formation by circulating neutrophils
Anna-Sophie Decker, Essen, Germany

Confirmed Speakers


Christian Blank, Amsterdam, Netherlands
Thomas Blankenstein, Berlin, Germany
Ezra Cohen, San Diego, USA
Lisa Derosa, Montreal, Canada
Bernardo S. Franklin, Bonn, Germany
Udo Gaipl, Erlangen, Germany
Thomas F. Gajewski, Chicago, USA
Frank Gieseler, Lübeck, Germany
Robert Haddad, Boston, USA
Iris Helfrich, Essen, Germany
Jochen Hess, Heidelberg, Germany
Dirk Jäger, Heidelberg, Germany
Dieter Kabelitz, Kiel, Germany
Ulrike Koehl, Leipzig, Germany
Frank Gieseler, Lübeck, Germany
Angela Krackhardt, München, Germany

Kirsten Lauber, München, Germany
Stephan Lang, Essen, Germany
Matthias Laudes, Kiel, Germany
Marco C. Merlano, Cuneo, Italy
Hans-Georg Rammensee, Tübingen, Germany
Licia Rivoltini, Mailand, Italy
Philip Rosenstiel, Kiel, Germany
Martina Seifert, Berlin, Germany
Tanguy Seiwert, Chicago, USA
Barbara Seliger, Halle, Germany
David Tamborero, Stockholm, Sweden
Eric Tartour, Paris, France
Ingeborg Tinhofer-Keilholz, Berlin, Germany
Viktor Umansky, Heidelberg, Germany
Therasa L. Whiteside, Pittsburgh, USA
Gunnar Wichmann, Leipzig, Germany